[Adenosine triphosphate in the treatment of supraventricular paroxysmal tachycardia: a comparison with verapamil].
OBJECTIVE
There are multiple drugs options in the treatment of Paroxysmal Supraventricular Tachycardia (PST) after inefficacious vagal stimulus. In this study we compare two of these treatments: verapamil versus adenosin triphosphate (ATP).


METHODS
Fifty patients with PST were randomly treated with either Verapamil (5 to 10 mg) or ATP (5 to 20 mg). The basal features of each group, and the efficacy and safety of the two drugs were compared. Verapamil failures were treated with ATP and vice versa.


RESULTS
The characteristics of both groups of treatment were similar. 86% of PST episodes were resolved with Verapamil use, versus 83% after ATP administration. Finally all patients were successfully treated with these drugs. No adverse effects were observed with Verapamil, whereas these effects were frequent with ATP use, but in any case requiring specific intervention.


CONCLUSIONS
Both Verapamil and aTP are an equally safe and effective treatment of PST, but transient and minor side effects are frequent after ATP administration.
Gil Madre
J
J
Servicio de Urgencias, Hospital Virgen de la Salud, Toledo.
Lázaro Rodríguez
S
S
Sentenac Merchán
G
G
Sepúlveda Berrocal
M A
MA
Alises Moraleda
J M
JM
Cortés Bermejo
S
S
García de Pedro
J
J
Laín Teres
N
N
D000255:Adenosine Triphosphate / Q000008:administration & dosage* / Q000009:adverse effects; D000328:Adult; D000368:Aged; D000075202:Contraindications; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D012074:Remission Induction; D013614:Tachycardia, Paroxysmal / Q000188:drug therapy*; D013617:Tachycardia, Supraventricular / Q000188:drug therapy*; D014700:Verapamil / Q000008:administration & dosage* / Q000009:adverse effects
D000255:Adenosine Triphosphate; D014700:Verapamil
Trifosfato de adenosina en el tratamiento de la taquicardia paroxística supraventricular: comparación con verapamilo.